Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects.
Lynne M MofensonAnton L PozniakJacque WambuiElliot RaizesAndrea L CiaranelloPolly ClaydenPeter D EhrenkranzAde FakoyaAndrew HillSaye H KhooImelda MahakaSurbhi ModiCynthia MooreAndrew N PhillipsGeorge SiberryKenly SikweseClaire ThorneHeather D WattsMeg DohertyNathan P FordPublished in: Journal of the International AIDS Society (2020)
The response to a signal suggesting a possible safety risk for a drug used in pregnancy or among women who may become pregnant needs to be rapid and comprehensive. It requires the existence of appropriately designed surveillance systems with broad population coverage; data analyses that examine risk-benefit trade-offs in a variety of contexts; guidance to transform this risk-benefit balance into effective and agreed-upon policy; involvement of the affected community and other key stakeholders; and a communication plan for all levels of knowledge and complexity. Implementation of this proposed framework for responding to safety signals is needed to ensure that any drug used in pregnancy can be rapidly and appropriately evaluated should a serious safety alert arise.